Navigation Links
Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
Date:9/19/2012

ceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company's lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a Phase II clinical trial for peripheral blood stem cell engraftment, and in earlier-stage trials for cord blood transplantation. TXA127 is also being developed, under grants from the US government, as a treatment for radiation exposure.

Tarix's second product, PanCyte, is a synthetic, long-acting analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on several disease areas with serious unmet medical need.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to the development of TXA127, including therapeutic indications, the development of the oral formulation of TXA127, additional feasibility programs evaluating Peptelligence™, application of Unigene technology to Tarix's other peptides, the licensing and financial arrangements between Unigene and Tarix for use of Unigene technology, Tari
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Unigene to Present at TIDES 2012
2. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
3. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
4. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Vesselon, Inc. today announced the appointment of Jurgen Raths, ... 2014. Dr. Raths, appointment follows Vesselon,s engagement with Spencer ... a private preferred Series A round to facilitate development ... "Jurgen,s deep experience across multiple functional areas of medical ... as we develop our device that can be compared ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/23/2014)... Mich. They are common suggestions to remedy stress: You ... Get out and see people. , Turns out ... better a lot better a new large scale ... lower depression, less perceived stress and enhanced mental health and ... Michigan, with partners from De Montfort University, James Hutton Institute, ...
(Date:9/23/2014)... ANGELES (September 23, 2014) Laparoscopic cholecystectomy, a minimally ... the most common abdominal surgeries in the U.S. Yet ... to the procedure with some moving patients quickly into ... online Monday in the American Journal of Surgery ... regular working hours rather than rushing the patients into ...
(Date:9/23/2014)... living things function comes from knowledge of structuresatomic details ... receptors that are docking stations for viruses and messenger ... carry genetic blueprints for building cellular machinery, to name ... structural details, a new grant just awarded by the ... of Energy (DOE) will fund the operation of a ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert ... is a 13-year veteran in the school, commercial and transit ... Bus Sales of Colton, California. While with A-Z Mr. Reynolds ... line revenues, profit and market penetration by double digits. , ... all-electric or plug-in hybrid vehicle conversions. They have converted ...
(Date:9/23/2014)... the European Journal of Cancer presents detailed ... the 1st EORTC Cancer Survivorship Summit held this past ... and more personalized multimodal treatments has boosted survival rates ... and rapidly increasing number of cancer survivors. Despite this ... broad spectrum of late adverse treatment effects and some ...
Breaking Medicine News(10 mins):Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:Study finds gallbladder surgery can wait 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2
... disease are there, researchers say , WEDNESDAY, Oct. 24 (HealthDay ... show early signs of heart disease -- similar to that ... by a team at Washington University School of Medicine, St. ... the children had undergone cardiac ultrasound to check on symptoms ...
... break-through new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... wants to help,people keep their joints hydrated and moving smoothly.* The ... Joint Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary ...
... ), the,global leader in the development, manufacture and supply ... today that it,will broadcast a third quarter 2007 earnings ... 2007 at 10:00 a.m. EDT. The call will,last approximately ... the opportunity to listen to,the conference call live at ...
... FRANCISCO While some targeted therapies drugs ... pathways occurring within cancer cells work well by ... when teamed with other targeted and conventional therapies. ... Molecular Targets and Cancer Therapeutics, multiple-target applications of new ...
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... 24 NutraCea (OTC Bulletin,Board: NTRZ), a health ... bran (SRB) nutrient research and technology whose products ... benefits for,humans and animals announced today that it ... relations services and an expanded,communications program among the ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: